Steve Rattner has a provocative op-ed in the NYTimes today %26lt;a href="http://opinionator.blogs.nytimes.com/2013/06/30/the-orphan-jackpot/"%26gt; link here%26lt;/a%26gt;. It focuses on a drug maker, Jazz Pharmaceuticals, which has found ways to make a "nothing" enterprise into a gold mine.
The company makes an orphan drug (one defined in law as a treatment for a condition affecting fewer than 200,000 people). It gets a 50 percent research-%26-development tax rate and 7 (vice 5 years for...
↧